
Samsung Biologics' Public Share Offering Draws KRW 11.4 Trillion
Samsung Biologics successfully completed a public share offering of KRW 2.7 trillion, fully subscribed, reflecting strong investor confidence.
Samsung Biologics successfully completed a public share offering of KRW 2.7 trillion, fully subscribed, reflecting strong investor confidence.
Samsung Biologics has announced the completion of its public share offering, raising approximately KRW 2.7 trillion. This offering was fully subscribed, indicating robust investor confidence in the company's growth prospects.
The public offering, conducted over two days on November 12 and 13, attracted a staggering KRW 11.4 trillion in subscription deposits, marking the highest amount ever recorded for such an offering in South Korea. The subscription ratio reached an impressive 135.6 to 1, showcasing the demand for the shares.
The funds raised will be allocated towards the acquisition of the Polypeptide Group, a strategic move that will enable Samsung Biologics to expand into the peptide business. This acquisition, valued at CHF 1.46 billion, is set to be the largest in the history of the Korean pharmaceutical and biotech sectors.
Samsung Biologics plans to issue a total of 2.27 million common shares at a price of KRW 1.174 million each. The completion of the paid-in capital increase is expected after the payment for shares on November 17, with new shares listed on the stock market on November 30.
Related companies
Where it matters
Related coverage

Korea Investment & Securities Raises Celltrion Target Price by 8%
Samsung Biologics' $2 Billion Rights Offering Oversubscribed
Samsung Biologics has successfully oversubscribed its recent $2 billion rights offering.
Woori Financial Group Launches 19th Goodwill Store for Disabilities Employment
Woori Financial Group has opened its 19th goodwill store to support job opportunities for individuals with developmental disabilities.
